|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | C12N 15/113 | |
| A61P 9/00 | |||
| A61K 47/54 | |||
| A61K 45/06 |
| (11) | Number of the document | 3146049 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15727527.2 |
| Date of filing the European patent application | 2015-05-22 | |
| (97) | Date of publication of the European application | 2017-03-29 |
| (45) | Date of publication and mention of the grant of the patent | 2020-02-26 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/032099 |
| Date | 2015-05-22 |
| (87) | Number | WO 2015/179724 |
| Date | 2015-11-26 |
| (30) | Number | Date | Country code |
| 201462001731 P | 2014-05-22 | US | |
| 201462047978 P | 2014-09-09 | US |
| (72) |
FOSTER, Donald, US
BETTENCOURT, Brian, US
CHARISSE, Klaus, US
HINKLE, Gregory, US
KUCHIMANCHI, Satyanarayana, US
MAIER, Martin, US
MILSTEIN, Stuart, US
|
| (73) |
Alnylam Pharmaceuticals, Inc.,
300 Third Street, 3rd Floor, Cambridge, MA 02142,
US
|
| (54) | ANGIOTENSINOGEN (AGT) IRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| ANGIOTENSINOGEN (AGT) IRNA COMPOSITIONS AND METHODS OF USE THEREOF |